Written with useful practicality in mind, Breast Pathology, 3rd Edition, provides surgical pathologists with authoritative guidance on the selection and best use of proper diagnostic techniques when reporting on breast specimens. Dr. David J. Dabbs and a team of internationally acclaimed pathologists incorporate genomic and molecular information, gross and microscopic findings, radiologic and laboratory diagnosis, theranostics, and immunohistochemistry to cover every aspect of benign and malignant lesions of the breast, helping you minimize diagnostic variation and error in the sign-out room.

• Brings you fully up to date with recent advances, including new molecular information for breast entities, new surgical techniques, more widely used multigene prognostic tests, and assays used to determine treatment, such as PD-L1 as a new immunotherapy biomarker for triple-negative breast cancer.

   

• Incorporates the latest classifications of breast pathology and molecular diagnosis.

   

• Organizes each topical chapter around relevant genomic and molecular information, clinical presentation, gross and microscopic pathologic findings and diagnostic and molecular immunohistochemistry.

   

• Maps immunohistochemistry for each entity according to diagnostic, theranostic, and genomic applications, with specific regard to disease entities in each chapter.

   

• Discusses breast specimen handling in detail to assure proper sampling and processing for optimal molecular and immunohistochemistry resulting.

   

• Supplies a convenient quick reference at the beginning of each chapter that includes all relevant diagnostic, theranostic, and genomic data for fast retrieval.

   

• Features approximately 2,000 full-color pathological images that clearly depict clinical, radiological, molecular, immunohistochemical, and theranostic aspects of disease.

   

• Includes biomarker guideline updates throughout.

   

• Reflects updates to new tumor staging data in the American Joint Committee on Cancer (AJCC) 8th Edition and updated ASCO/CAP guidelines for interpreting HER2 assays.